Expression and clinical significance of MAGE-C1 in breast cancer tissues
10.3872/j.issn.1007-385x.2020.10.007
- VernacularTitle:MAGE-C1在乳腺癌组织中的表达及其临床意义
- Author:
LI Nan
1
;
SHAN Baoen
2
;
ZHAO Lianmei
2
;
GU Guang
3
;
HOU Shuyun
4
Author Information
1. 1a. Department of Oncology
2. 2. Department of Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050019, Hebei, China
3. 1b. Department of Rheumatology and Immunology, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei, China
4. 1a. Department of Oncology, 1b. Department of Rheumatology and Immunology, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei, China
- Publication Type:Journal Article
- Keywords:
melanoma-associated antigen-C1 (MAGE-C1);
cancer testis antigens;
breast cancer;
recurrence-free survival (RFS);
immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
2020;27(10):1112-1117
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To investigate the expression of MAGE-C1 (melanoma-associated antigen-C1) in breast cancer tissues and its
correlation with clinicopathological features and prognosis of breast cancer patients. Methods: Breast cancer tissues, normal breast
tissues and benign breast lesion tissues (60 samples for each) were collected from the Fourth Hospital of Hebei Medical University
during January 2008 and December 2008.The mRNA and protein expressions of MAGE-C1 in three types of breast tissues were detected
by RT-PCR and immunohistochemistry, and their correlation with clinicopathological parameters and prognosis of breast cancer
patients were also analyzed. DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-Aza-CdR) and histone deacetylase inhibitor trichostatin
A (TSA) were used to treat breast cancer MDA-MB-231 and MCF-7 cells, and RT-PCR was used to determine the changes in mRNA
expression of MAGE-C1 after drug treatment. Results: The positive expression rate of MAGE-C1 mRNA and protein in breast cancer
tissues were 43.3% (26/60) and 38.3% (23/60), respectively; and the mRNA and protein expressions of MAGE-C1 were all negative
in normal breast tissues and benign breast lesion tissues. MAGE-C1 expression was positively associated with high tumor grade
(χ2
=6.233, P<0.05). Recurrence-free survival (RFS) of patients with negative MAGE-C1 expression was significantly longer than
those patients with positive MAGE-C1 expression (χ 2
=4.213, P<0.05). MAGE-C1 expression (HR=3.980, P<0.05) and clinical
stage (HR=3.637, P<0.05) could be used as independent prognostic factors for breast cancer patients. 5-Aza-CdR and/or TSA treatment
had no significant influence on MAGE-C1 gene expression (P>0.05). Conclusion: MAGE-C1 is a tumor-specific antigen and its
expression is associated with poor prognosis of breast cancer patients.
- Full text:20201007.pdf
